{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:54:04Z","timestamp":1790276044403,"version":"4.1.0"},"reference-count":97,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) is one of the critical infectious complications related to host immune recovery. The spectrum of CMV infection is quite extensive, from asymptomatic CMV reactivation presenting mainly as CMV DNAemia to fatal CMV diseases involving gut, liver, lungs, or brain. In addition to organ involvement, CMV reactivation can exert indirect effects such as immunosuppression or graft failure that may result in the development of concurrent infectious complications. Currently, preemptive therapy, which is based on PCR-based monitoring of CMV from blood, is a mainstay enabling improvement in CMV-related outcomes. During the past decades, new antiviral drugs, clinical trials for prophylaxis in high-risk groups, and vaccines for preventing CMV infection have been introduced. In addition, data for immunologic monitoring and adoptive immunotherapy have also been accumulated. Here, we review the current status and recent updates in this field, with future perspectives including immunotherapy in HSCT recipients.<\/jats:p>","DOI":"10.3390\/ijms20112666","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T11:07:44Z","timestamp":1559214464000},"page":"2666","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy"],"prefix":"10.3390","volume":"20","author":[{"given":"Sung-Yeon","family":"Cho","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Gun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[{"name":"Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Division of Hematology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"},{"name":"Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3904\/kjim.2018.036","article-title":"Infectious complications after hematopoietic stem cell transplantation: Current status and future perspectives in Korea","volume":"33","author":"Cho","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.hoc.2010.11.008","article-title":"Hematopoietic stem cell transplantation: An overview of infection risks and epidemiology","volume":"25","author":"Wingard","year":"2011","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cid\/cir492","article-title":"Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: Neutropenia, humoral, and splenic defects","volume":"53","author":"Safdar","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: Pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J. Clin. Invest."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.2217\/fmb-2017-0095","article-title":"Current and future Current and future options for cytomegalovirus reactivation in hematopoietic cell transplantation patients","volume":"12","author":"Maertens","year":"2017","journal-title":"Future Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ophtha.2012.03.032","article-title":"Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation","volume":"119","author":"Jeon","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_8","first-page":"3359","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: A report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Labopin","year":"2013","journal-title":"Blood"},{"key":"ref_9","first-page":"e1","article-title":"Polish Society of Paediatric Oncology and Haematology. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: A multicentre nationwide study","volume":"179","author":"Styczynski","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: A CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: A retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ofx050","DOI":"10.1093\/ofid\/ofx050","article-title":"Infections in hematopoietic cell transplant recipients: Results from the organ transplant infection project, a multicenter, prospective, cohort study","volume":"4","author":"Schuster","year":"2017","journal-title":"Open Forum Infect. Dis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/sj.bmt.1704505","article-title":"European Group for Blood and Marrow Transplantation. Management of CMV infections: Recommendations from the infectious diseases working party of the EBMT","volume":"33","author":"Ljungman","year":"2004","journal-title":"Bone Marrow Transpl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39736","DOI":"10.18632\/oncotarget.14504","article-title":"Diagnosis of cytomegalovirus pneumonia by quantitative polymerase chain reaction using bronchial washing fluid from patients with hematologic malignancies","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1086\/318721","article-title":"Cytomegalovirus pneumonia in adults with leukemia: An emerging problem","volume":"32","author":"Nguyen","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/cid\/civ215","article-title":"Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices","volume":"61","author":"Erard","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How I treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbmt.2014.11.002","article-title":"Recent advances in cytomegalovirus: An update on pharmacologic and cellular therapies","volume":"21","author":"Boeckh","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbmt.2017.09.018","article-title":"Prevention of Cytomegalovirus reactivation in haploidentical stem cell transplantation","volume":"24","author":"Hammerstrom","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"Li","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1399-3062.2009.00414.x","article-title":"Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: Comparison with anti-thymocyte globulin","volume":"11","author":"Park","year":"2009","journal-title":"Transpl. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-06-688432","article-title":"How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients","volume":"128","author":"Chaer","year":"2016","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"French CMV Resistance Survey Study Group. Drug-resistant cytomegalovirus in transplant recipients: A French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkn521","article-title":"Valganciclovir as pre-emptive therapy for cytomegalovirus infection post- allogenic stem cell transplantation: Implications for the emergence of drug-resistant cytomegalovirus","volume":"63","author":"Allice","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3851\/IMP1899","article-title":"Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients","volume":"17","author":"Marijt","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2009-12-234096","article-title":"Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: An update","volume":"115","author":"Seggewiss","year":"2010","journal-title":"Blood"},{"key":"ref_32","first-page":"6551","article-title":"Risk factors for cytomegalovirus infection after allogeneic hematopoietic cell transplantation in malignancies: Proposal for classification","volume":"37","author":"Dziedzic","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who Is the patient at risk of CMV recurrence: A review of the current scientific evidence with a focus on hematopoietic cell transplantation","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation; UK Virology Network. Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/clinids\/14.4.831","article-title":"Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group","volume":"14","author":"Ljungman","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/bbmt.2002.v8.pm11939601","article-title":"Intravenous immunoglobulin: Appropriate indications and uses in hematopoietic stem cell transplantation","volume":"8","author":"Sokos","year":"2002","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antiviral Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance","volume":"59","author":"Chow","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J. Clin. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1345\/aph.1L065","article-title":"Maribavir: A novel antiviral agent with activity against cytomegalovirus","volume":"42","author":"Trofe","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?","volume":"1","author":"Marty","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","article-title":"In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review","volume":"163","author":"Chemaly","year":"2019","journal-title":"Antiviral Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcv.2016.12.006","article-title":"Successful oral treatment of ganciclovir resistant cytomegalovirus with maribavir in the context of primary immunodeficiency: First case report and review","volume":"87","author":"Bright","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref_51","unstructured":"Papanicolaou, G.A., Silveira, F.P., Langston, A.A., Pereira, M.R., Avery, R.K., Uknis, M., Wijatyk, A., Wu, J., Boeckh, M., and Marty, F.M. (2018). Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, phase 2 Study. Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.bbmt.2018.05.017","article-title":"Comparative efficacy and safety of different antiviral agents for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis","volume":"24","author":"Gagelmann","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcv.2017.09.013","article-title":"Disseminated adenovirus infection after allogeneic stem cell transplant and the potential role of brincidofovir\u2014Case series and 10 year experience of management in an adult transplant cohort","volume":"96","author":"Ramsay","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_56","unstructured":"Bennett, J.E., Dolin, R., and Blaser, M.J. (2014). Cytomegalovirus. Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1007\/s00018-015-1986-z","article-title":"The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients","volume":"72","author":"Zabalza","year":"2015","journal-title":"Cell Mol. Life Sci."},{"key":"ref_58","unstructured":"Plotkin, S.A., Orenstein, W.A., Offit, P.A., and Edwards, K.M. (2018). Vaccination of immunocompromised hosts. Plotkin\u2019s Vaccines, Elsevier."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbmt.2003.12.004","article-title":"Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants","volume":"10","author":"Lacey","year":"2004","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/bmt.2010.261","article-title":"Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT","volume":"46","author":"Kalina","year":"2011","journal-title":"Bone Marrow Transpl."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/21505594.2016.1221022","article-title":"CMV-specific immune reconstitution following allogeneic stem cell transplantation","volume":"7","author":"Blyth","year":"2016","journal-title":"Virulence"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lilleri, D., Gerna, G., Zelini, P., Chiesa, A., Rognoni, V., Mastronuzzi, A., Giorgiani, G., Zecca, M., and Locatelli, F. (2012). Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0041648"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2002-11-3472","article-title":"Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: Impact of host factors, drug therapy, and subclinical reactivation","volume":"102","author":"Hakki","year":"2003","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Widmann, T., Sester, U., G\u00e4rtner, B.C., Schubert, J., Pfreundschuh, M., K\u00f6hler, H., and Sester, M. (2008). Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003634"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM198207013070102","article-title":"Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients","volume":"307","author":"Quinnan","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2017.03.027","article-title":"Possible impact of cytomegalovirus-specific CD8+ T cells on immune reconstitution and conversion to complete donor chimerism after allogeneic stem cell transplantation","volume":"23","author":"Ogonek","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fimmu.2018.00389","article-title":"Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation","volume":"9","author":"Litjens","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"17230","DOI":"10.18632\/oncotarget.7347","article-title":"Impact of cytomegalovirus reactivation on relapse and survival in patients with acute leukemia who received allogeneic hematopoietic stem cell transplantation in first remission","volume":"7","author":"Yoon","year":"2016","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-04-713644","article-title":"Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia","volume":"128","author":"Elmaagacli","year":"2016","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00277-014-2190-1","article-title":"Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia","volume":"94","author":"Jang","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nri818","article-title":"Suppressors of cytokine signalling (SOCS) in the immune system","volume":"2","author":"Alexander","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2009-12-259598","article-title":"SOCS3 regulates graft-versus-host disease","volume":"116","author":"Hill","year":"2010","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5045\/br.2013.48.1.16","article-title":"Expression of SOCS1 and SOCS3 genes in human graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"48","author":"Lee","year":"2013","journal-title":"Blood Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5045\/br.2015.50.1.40","article-title":"SOCS1 and SOCS3 are expressed in mononuclear cells in human cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation","volume":"50","author":"Shin","year":"2015","journal-title":"Blood Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/infdis\/jix192","article-title":"Identifying cytomegalovirus complications using the quantiferon-CMV assay after allogeneic hematopoietic stem cell transplantation","volume":"215","author":"Yong","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jcv.2016.11.012","article-title":"Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients","volume":"87","author":"Jung","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1086\/588385","article-title":"Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects","volume":"197","author":"Wloch","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2055-6640(20)30872-4","article-title":"Cytomegalovirus vaccines under clinical development","volume":"2","author":"Schleiss","year":"2016","journal-title":"J. Virus Erad."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Boeckh","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/vaccines1040398","article-title":"Clinical development of a cytomegalovirus DNA vaccine: From product concept to pivotal phase 3 trial","volume":"1","author":"Smith","year":"2013","journal-title":"Vaccines"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1128\/AAC.02698-15","article-title":"A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers","volume":"60","author":"Dole","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/21505594.2016.1207038","article-title":"Immunotherapy for opportunistic infections: Current status and future perspectives","volume":"7","author":"Fuji","year":"2016","journal-title":"Virulence"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14712590903456003","article-title":"Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation","volume":"10","author":"Leen","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood.V97.4.994","article-title":"Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: A novel culture system free of live CMV virions","volume":"97","author":"Peggs","year":"2001","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/QCO.0000000000000375","article-title":"Cytomegalovirus disease in hematopoietic stem cell transplant patients: Current and future therapeutic options","volume":"30","author":"Fuji","year":"2017","journal-title":"Curr. Opin. Infect. Dis"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000479238","article-title":"Robust Production of Cytomegalovirus pp65-Specific T Cells using a fully automated IFN-\u03b3 cytokine capture system","volume":"45","author":"Kim","year":"2018","journal-title":"Transfus. Med. Hemother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/infdis\/jix357","article-title":"Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: The quantitative and qualitative immune recovery for cytomegalovirus","volume":"216","author":"Pei","year":"2017","journal-title":"J. Infect. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/11\/2666\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:54:47Z","timestamp":1760187287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/11\/2666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":97,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["ijms20112666"],"URL":"https:\/\/doi.org\/10.3390\/ijms20112666","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]}}}